cancers-logo

Journal Browser

Journal Browser

Exosomes in Cancer Metastasis (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".

Deadline for manuscript submissions: 10 November 2026 | Viewed by 3516

Special Issue Editor


E-Mail Website
Guest Editor
Cancer Center, Department of Pathology, University of Pittsburgh School of Medicine and UPMC Hillman, Pittsburgh, PA 15213, USA
Interests: exosomes; tumor immunology; immunotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of a previous one, entitled "Exosomes in Cancer Metastasis" (https://www.mdpi.com/journal/cancers/special_issues/C3K45PNV8A).

In 1889, Stephen Paget formulated his “seed and soil” hypothesis that compared tumor cells to “the seed”, requiring a supportive tissue environment, “the soil”, for establishing organotropic metastasis (Paget S. The distribution of secondary growths in cancer of the breast. Lancer 133, 571–673, 1889). Since then, research on the mechanisms responsible for metastasis has been largely focused on interactions between the tumor and the host. Over the years, these interactions under the general label of the “tumor–host cell crosstalk” focused on various modes of intercellular communication mediated by growth factors, cytokines/chemokines, integrins, immune cells, or a broad variety of other signals that promoted metastasis (Müller, A. et al., 2001 [1]; Hoshino, A. et al., 2015 [2]; Sun, L. et al., 2021 [3]). As our understanding of intercellular communication increased, it became clear that no one factor or mechanism could explain organotropic metastases. A broad variety of mechanisms that have been described largely failed to explain who or what prepared the “soil’’ in various organs and what exactly was the “seed” delivered to the prepared soil that resulted in metastasis. Who or what regulated the metastatic spread? Was it the growing tumor or the host fighting for survival?

These and other questions remain unanswered today. However, research progress has changed, mainly due to the emergence of extracellular vesicles (EVs) as the prime mediators of intercellular communication that is more efficient and more closely and specifically targeted than any other cellular interaction (Kalluri, R. et al., 2020 [4]; Wortzel, I. et al., 2019 [5]). EVs are present in all body fluids and are capable of crossing all organ barriers (Banks, W.A. et al., 2022 [6]).

They carry their cargo in the lumen, where it is protected from exogenous degradation by the surface membrane, and deliver it to recipient cells in the native form. The surface of EVs is not biologically idle; it is decorated by a host of receptor/ligands that can engage recipient cells. Thus, freely circulating tumor-derived EVs aspire to be an almost perfect mechanism for conveying signals from tumor cells to near or distant sites in preparation for metastasis.

While this view of circulating tumor-derived EVs as a mechanism for converting distant normal tissues and cells into pro-tumor facilitators is attractive, many unanswered questions exist. For one, we have no information about how tumor-derived EVs are directed to an organ and how exactly they arrive there. Additionally, once at the site, how do the EVs engage specific tissue cells? Once engaged, which components of the exosome cargo, i.e., proteins, lipids, or nucleic acids, delivered to recipient cells are responsible for inducing pro-metastatic changes? Can microvesicles (MVs) be more effective in shaping pre-metastatic changes than small EVs? Are the direct effects of tumor-derived EVs the only or the major pro-metastatic mechanism? Can the indirect interactions of EVs with immune or neural systems be involved in creating the pro-metastatic niche? Answering these questions is of prime importance for unraveling the complex mesh of molecular interactions that underlie metastasis. Much effort is needed, and it is encouraging to see that research into Paget’s hypothesis is rapidly embracing the subcellular interactions mediated by nanovesicles.

It is expected that this Special Issue will provide a forum for the exchange of new knowledge about cell–cell communication via EVs that will shape future therapeutic initiatives.  We are especially interested in exosomes as biomarkers of metastasis. Metastasis must be stopped or eliminated to save lives, and the understanding of its basic molecular insights is the surest way to future clinical success.

References

  1. Müller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M.E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S.N.; et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50–56.
  2. Hoshino, A.; Costa-Silva, B.; Shen, T.-L.; Rodrigues, G.; Hashimoto, A.; Mark, M.T.; Molina, H.; Kohsaka, S.; Di Giannatale, A.; Ceder, S.; et al. Tumour exosome integrins determine organotropic metastasis. Nature 2015, 527, 329–335.
  3. Sun, L.; Kees, T.; Almeida, A.S.; Liu, B.; He, X.-Y.; Ng, D.; Han, X.; Spector, D.L.; McNeish, I.A.; Gimotty, P.; et al. Available online: https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00445-1 (accessed on 7 August 2023).
  4. Kalluri, R.; Lebleu, V.S. The biology, function, and biomedical applications of exosomes. Science 2020, 367, 6478.
  5. Wortzel, I.; Dror, S.; Kenific, C.M.; Lyden, D. Available online: https://www.cell.com/developmental-cell/fulltext/S1534-5807(19)30281-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1534580719302813%3Fshowall%3Dtrue (accessed on 7 August 2023).
  6. Banks, W.A.; Sharma, P.; Hansen, K.M.; Ludwig, N.; Whiteside, T.L. Characteristics of Exosomes and the Vascular Landscape Regulate Exosome Sequestration by Peripheral Tissues and Brain. Int. J. Mol. Sci. 2022, 23, 12513.

Prof. Dr. Theresa L. Whiteside
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • exosomes
  • biomarkers
  • cancer metastasis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 1852 KB  
Article
Extracellular Vesicle-Mediated Delivery of Curcumin Suppresses Tumor Progression in Murine Oral Squamous Cell Carcinoma
by Nils Ludwig, Carolin Feldmann, Silvia Spoerl and Saigopalakrishna S. Yerneni
Cancers 2026, 18(10), 1586; https://doi.org/10.3390/cancers18101586 - 13 May 2026
Viewed by 85
Abstract
Rationale: Oral squamous cell carcinoma (OSCC) carries a poor prognosis despite advances in multimodal therapy. Nanomedicine represents a compelling strategy to enhance targeted drug delivery and improve therapeutic outcomes. Here, we investigated sEV-mediated delivery of curcumin as a novel therapeutic approach for [...] Read more.
Rationale: Oral squamous cell carcinoma (OSCC) carries a poor prognosis despite advances in multimodal therapy. Nanomedicine represents a compelling strategy to enhance targeted drug delivery and improve therapeutic outcomes. Here, we investigated sEV-mediated delivery of curcumin as a novel therapeutic approach for OSCC. Methods: Small extracellular vesicles (sEVs) were isolated from Jurkat cells by size-exclusion chromatography and loaded with curcumin via sonication to generate JCsEV. Functional effects were assessed in vitro using wound healing, transwell invasion, and metabolic activity assays across multiple cancer cell lines. Therapeutic efficacy in vivo was evaluated in the 4-nitroquinoline 1-oxide (4-NQO) immunocompetent murine model of oral carcinogenesis. Female C57BL/6J mice received intraperitoneal treatment for four weeks with PBS, free curcumin, unloaded JsEV, or JCsEV. Tumor number, tumor burden, and body weight changes were assessed at the experimental endpoint. Results: In vitro, JCsEV significantly inhibited tumor cell migration, invasion, and metabolic activity compared with controls (p < 0.05). In vivo, treatment with JCsEV significantly reduced tumor number and tumor burden in the 4-NQO model (p < 0.01). In addition, body weight loss was reduced in JCsEV-treated mice compared with controls. Conclusion: sEV-mediated delivery of curcumin effectively suppresses tumor progression in experimental OSCC. These findings establish proof-of-concept for sEV-based nanomedicine as a therapeutic strategy for OSCC and provide a compelling rationale for further translational investigation of sEVs as drug delivery platforms. Full article
(This article belongs to the Special Issue Exosomes in Cancer Metastasis (2nd Edition))
Show Figures

Figure 1

12 pages, 3854 KB  
Article
Crosstalk of Tumor-Derived Extracellular Vesicles with Immune Recipient Cells and Cancer Metastasis
by Han Jie, Alicja C Gluszko and Theresa L. Whiteside
Cancers 2026, 18(2), 196; https://doi.org/10.3390/cancers18020196 - 7 Jan 2026
Viewed by 784
Abstract
Background. Contributions of tumor-derived extracellular vesicles, TEX, to tumor progression and metastasis involve their crosstalk with immune cells in the tumor microenvironment. This crosstalk results in metabolic reprogramming of immune cells from anti-tumor to pro-tumor activity. Mechanistic underpinnings of the TEX entry [...] Read more.
Background. Contributions of tumor-derived extracellular vesicles, TEX, to tumor progression and metastasis involve their crosstalk with immune cells in the tumor microenvironment. This crosstalk results in metabolic reprogramming of immune cells from anti-tumor to pro-tumor activity. Mechanistic underpinnings of the TEX entry and delivery of molecular signals responsible for metabolic reprogramming may be unique for different types of immune cells. Methods. An in vitro model of THP-1 myeloid cells co-incubated with TEX illustrates the role TEX play in polarization of macrophages to TAMs. Results. In THP-1 cells, the dominant signaling pathway of melanoma cell-derived TEX involves HSP-90/TLR2. This leads to activation of the NF-κB and MAP kinase pathways and initiates THP-1 cell polarization from M0 to M2 with strong expression of immunosuppressive PD-L1. TEX may be seen as “danger” by the myeloid cells, which utilize the pattern recognition receptors (PRR), such as PAMPs or DAMPs, for engaging the complementary ligands carried by TEX. The same melanoma TEX signaling to T cells via DAMPs induced mitochondrial stress, resulting in T-cell apoptosis. Conclusions. As the signaling receptors/ligands in TEX are determined by the tumor, it appears that the tumor equips TEX with an address recognizing specific PRRs expressed on different recipient immune cells. Thus, TEX, acting like pathogens, are equipped by the tumor to alter the context of intercellular crosstalk and impose a distinct autophagy-not-apoptosis signature in recipient THP-1 cells. The tumor might endorse TEX to promote tumor progression and metastasis by enabling them to engage the signaling system normally used by immune cells for defense against pathogens. Full article
(This article belongs to the Special Issue Exosomes in Cancer Metastasis (2nd Edition))
Show Figures

Figure 1

20 pages, 6964 KB  
Article
Comprehensive Profiling of Serum Exosomes by a Multi-Omics Approach Reveals Potential Diagnostic Markers for Brain Metastasis in Lung Cancer
by Jiwoo Lim, Mia Kang, Young-Ho Ahn, Min-Sun Cho, Jin Hwa Lee, Jihee Lee Kang and Youn-Hee Choi
Cancers 2025, 17(12), 1929; https://doi.org/10.3390/cancers17121929 - 10 Jun 2025
Cited by 5 | Viewed by 2135
Abstract
Background: Brain metastasis occurs in 40–50% of lung cancer patients and is associated with poor prognosis. This study aimed to identify potential exosomal biomarkers for the early detection of brain metastasis in lung cancer using a comprehensive multi-omics approach. Methods: Using a lung [...] Read more.
Background: Brain metastasis occurs in 40–50% of lung cancer patients and is associated with poor prognosis. This study aimed to identify potential exosomal biomarkers for the early detection of brain metastasis in lung cancer using a comprehensive multi-omics approach. Methods: Using a lung cancer mouse model, which develops brain metastasis, we collected serum samples at different stages (control, 6 weeks for lung cancer, and 10 weeks for brain metastasis). We profiled the contents of serum-derived exosomes using small RNA sequencing and LC-MS/MS proteomic analysis, and assessed the clinical relevance of candidate biomarkers using publicly available patient datasets. Results: RNA sequencing identified 11 differentially expressed miRNAs across disease progression, with miR-206-3p showing significant upregulation during brain metastasis. Pathway analysis of miR-206-3p targets revealed enrichment in cancer-related pathways, including Hippo, MAPK, Ras, and PI3K-Akt signaling. Proteomic analysis revealed 77 proteins specifically upregulated in the brain metastasis stage, with vinculin (VCL) emerging as a promising marker. While VCL expression decreased in lung tissues and showed no significant changes in brain tissues, its levels were significantly elevated in serum-derived exosomes during brain metastasis. Clinical database analysis revealed that higher VCL expression correlated with poor patient survival. Conclusions: Our study identified exosomal miR-206-3p and VCL as promising non-invasive biomarkers for brain metastasis in lung cancer using the mouse model. These findings provide new opportunities for early detection and monitoring of brain metastasis, potentially enabling timely therapeutic intervention. Full article
(This article belongs to the Special Issue Exosomes in Cancer Metastasis (2nd Edition))
Show Figures

Figure 1

Back to TopTop